Schikan Johannes Gerardus Christiaan Petrus sold $7.0M of PHVS

Schikan Johannes Gerardus Christiaan Petrus sold 200,000 shares of Pharvaris N.V. (PHVS) at $35.00 ($7.00M total) on 2026-09-17.

Original reporting
SEC EDGAR · Schikan Johannes Gerardus Christiaan Petrus
Published Sep 21, 2026, 8:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 21, 2026, 8:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PHVS
Bearish
medium confidence
Mentioned
$PHVS
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PHVSBearishLow
01

Why it matters

Direct insider sell could signal negative sentiment.

02

Market read

Primary disclosure of a sizable insider sale.

03

What to watch

No immediate catalyst; sale could be routine liquidity need.

Relevance 6/10Novelty 6/10Timing: post-filing 2026-09-21

Background

SEC Form 4 filing discloses insider transaction.

Company-level read

Ticker impact

$PHVSBearishMedium confidence
Context

Director sold 200,000 shares for $7M, reducing his stake to 115,167 shares.

Expected impact

Potential downward pressure over next few days.

Evidence & confidence

Large sale by a director suggests possible concerns about valuation.

Market effects

May affect biotech sector sentiment as insider sales are monitored.

Limited to US biotech investors.

Low global impact.

Counterpoint

Insider may be diversifying, not necessarily bearish.

Key entities

  • Schikan Johannes Gerardus Christiaan Petrus

    Insider selling shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PHVSMed

Pharvaris reports Q3 results

Pharvaris reported a Q3 EPS of -$0.67, with cash reserves of €283M as of September 30, 2026, down from €292M at year-end 2025. The company's net loss widened to €47.4M, up from €37.1M year-over-year. Recently, Pharvaris presented at healthcare conferences and announced positive late-stage trial results for its hereditary angioedema drug, leading to an upgrade by BofA to 'Buy'.

$PHVSMedAI 8/10

Pharvaris (PHVS) Reports Q3 Results After Phase 3 Milestone

Pharvaris (PHVS) reported Q3 2026 results, highlighting FDA review of deucrictibant IR NDA with a 2027 PDUFA date. Phase 3 study data for deucrictibant XR expected in 1Q2027. NDA submission for deucrictibant XR in AE-BK attacks planned for 1H2027. Cash position of €283M as of Q3 2026. No financial figures provided for Q3.